• centos7搭建shadowsock
  • Investors
  • English
  • linux安装shadowsock
  • 日本語

Poxel SA

toto加速器-toto加速器官网-toto加速器最新版-toto加速器

For our lead product, Imeglimin, preparations are underway for a New Drug Application in Japan. Imeglimin has successfully completed Phase 2 development in the U.S. and EU. PXL770 and PXL065 are in mid-stage development for NASH. We are also evaluating our AMPK activation and TZD platforms for other chronic and rare metabolic diseases.

View Our Candidates
Targeting Mitochondrial Dysfunction

toto加速器-toto加速器官网-toto加速器最新版-toto加速器

Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for type 2 diabetes and NASH.

View Pipeline
Innovative Pipeline of First-In-Class Products

toto加速器-toto加速器官网-toto加速器最新版-toto加速器

Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.

Meet Our Team
centos7搭建shadowsock

toto加速器-toto加速器官网-toto加速器最新版-toto加速器

toto加速器-toto加速器官网-toto加速器最新版-toto加速器

Japanese New Drug Application (J-NDA) for Imeglimin is supported by an extensive preclinical and clinical program, including positive results from the Phase 3 TIMES program in over 1,100 patients in Japan Imeglimin…

Read this Press Release: Poxel Announces Submission of Imeglimin Japanese New Drug Application for the Treatment of Type 2 Diabetes by Sumitomo Dainippon Pharma

toto加速器-toto加速器官网-toto加速器最新版-toto加速器

Poxel completed a capital raise of EUR 17.7 million (USD 19.4 million) to accelerate development of PXL770 and PXL065 in NASH and to pursue early-stage opportunities for pipeline growth from its…

Read this Press Release: Poxel Provides Corporate Update and Reports Cash and Revenue for the Second Quarter and First Half 2024

toto加速器-toto加速器官网-toto加速器最新版-toto加速器

Shareholders approved all proposed resolutions   LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for…

Read this Press Release: Poxel Announces Results from June 24, 2024 Ordinary Annual and Extraordinary General Meeting
linux安装shadowsock Click here to show the next slide

toto加速器-toto加速器官网-toto加速器最新版-toto加速器

European Association for the Study of the Liver 2024 International Liver Congress

Click here to show the previous slide Click here to show the next slide
centos7搭建shadowsock
View Investor Relations
View Investor Presentation
雷轰加速器官网,比特加速器邮箱登录,彗星vp加速器,link加速器  飞轮加速器最新版,飞轮加速器7天试用,飞轮加速器用不了了,飞轮加速器vqn  快连vp加速器,快连vpv加速器,快连vn官网下载,  葫芦加速器最新版,葫芦加速器官方网址,葫芦加速器安卓下载,葫芦加速器永久免费加速  一元机场梯子,赔钱机场梯子,赔钱机场订阅链接在哪,一元机场加速器  豆荚加速器官网,豆荚加速器下载地址,豆荚加速器npv,豆荚加速器跑路了  月付机场vnp,月付机场永久免费加速,月付机场打不开,月付机场vqn